Christopher de Souza

Christopher de Souza has held various roles in multiple companies throughout their career. In 2012, they started as the Director of Broadview Ventures, a position they still hold. Christopher also served as a Board Observer for Acesion Pharma from December 2014 onwards and for Pulmokine Inc from February 2015 onwards. In 2016, they became a Board Director for Gila Therapeutics and MassBio, where they served until November 2021. In the same year, they also joined Giner Life Sciences as a Member of the Board of Directors. Starting in 2017, de Souza became a Board Director for Mellitus, LLC. Christopher assumed the role of Chair for the Translation Awards Committee at the British Heart Foundation in November 2018 and served until May 2021. Additionally, they became a Director at Longview Ventures in January 2019. Lastly, they served as a Board Observer for Allosteros Therapeutics Inc. from September 2012 until December 2019.

Christopher de Souza obtained a Bachelor of Science (BSc) and Master of Science (MSc) degree in Zoology and Biochemistry from the University of Mumbai between 1978 and 1983. Following this, they pursued further education at Louisiana State University from 1983 to 1991, where they obtained both a Master of Science (MS) and a Doctor of Philosophy (PhD) degree in Endocrine Physiology. Lastly, between 2001 and 2003, Christopher completed their Master of Business Administration (MBA) degree in Management at Rutgers University - Newark.